118 related articles for article (PubMed ID: 26529134)
1. Budesonide rectal foam (Uceris) for ulcerative colitis.
Med Lett Drugs Ther; 2015 Nov; 57(1481):154. PubMed ID: 26529134
[No Abstract] [Full Text] [Related]
2. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis.
Gross V; Bar-Meir S; Lavy A; Mickisch O; Tulassay Z; Pronai L; Kupcinskas L; Kiudelis G; Pokrotnieks J; Kovács A; Faszczyk M; Razbadauskas A; Margus B; Stolte M; Müller R; Greinwald R;
Aliment Pharmacol Ther; 2006 Jan; 23(2):303-12. PubMed ID: 16393311
[TBL] [Abstract][Full Text] [Related]
3. Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis.
Naganuma M; Aoyama N; Suzuki Y; Nishino H; Kobayashi K; Hirai F; Watanabe K; Hibi T
J Crohns Colitis; 2016 Jul; 10(7):828-36. PubMed ID: 26577683
[TBL] [Abstract][Full Text] [Related]
4. Controlled, open, randomized multicenter trial comparing the effects of treatment on quality of life, safety and efficacy of budesonide foam and betamethasone enemas in patients with active distal ulcerative colitis.
Hammond A; Andus T; Gierend M; Ecker KW; Scholmerich J; Herfarth H;
Hepatogastroenterology; 2004; 51(59):1345-9. PubMed ID: 15362749
[TBL] [Abstract][Full Text] [Related]
5. [Budesonide foam as a new therapeutic principle in distal ulcerative colitis in comparison with mesalazine enema. An open, controlled, randomized and prospective multicenter pilot study].
Rufle W; Frühmorgen P; Huber W; Kimmig JM
Z Gastroenterol; 2000 Apr; 38(4):287-93. PubMed ID: 10820860
[TBL] [Abstract][Full Text] [Related]
6. Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study.
Naganuma M; Aoyama N; Tada T; Kobayashi K; Hirai F; Watanabe K; Watanabe M; Hibi T
J Gastroenterol; 2018 Apr; 53(4):494-506. PubMed ID: 28779419
[TBL] [Abstract][Full Text] [Related]
7. [Topical steroids in chronic inflammatory bowel diseases].
Fleig WE
Internist (Berl); 1997 Dec; 38(12):1154-9. PubMed ID: 9465320
[No Abstract] [Full Text] [Related]
8. [Patients prefer foam].
MMW Fortschr Med; 2007 May; 149(21):48. PubMed ID: 17668735
[No Abstract] [Full Text] [Related]
9. Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis.
Rubin DT; Sandborn WJ; Bosworth B; Zakko S; Gordon GL; Sale ME; Rolleri RL; Golden PL; Barrett AC; Bortey E; Forbes WP
Dig Dis Sci; 2015 Nov; 60(11):3408-17. PubMed ID: 26386854
[TBL] [Abstract][Full Text] [Related]
10. Budesonide MMX(®): a review of its use in patients with mild to moderate ulcerative colitis.
Hoy SM
Drugs; 2015 May; 75(8):879-86. PubMed ID: 25920500
[TBL] [Abstract][Full Text] [Related]
11. [Treating distal ulcerative colitis intrarectally. Foam instead of enema, low volume rather than high volume].
MMW Fortschr Med; 2008 Apr; 150(15):44. PubMed ID: 18510119
[No Abstract] [Full Text] [Related]
12. Colonic spread and serum pharmacokinetics of budesonide foam in patients with mildly to moderately active ulcerative colitis.
Brunner M; Vogelsang H; Greinwald R; Kletter K; Kvaternik H; Schrolnberger C; Eichler HG; Brunner H; Dudczak R; Müller M
Aliment Pharmacol Ther; 2005 Sep; 22(5):463-70. PubMed ID: 16128685
[TBL] [Abstract][Full Text] [Related]
13. Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis.
Hartmann F; Stein J;
Aliment Pharmacol Ther; 2010 Aug; 32(3):368-76. PubMed ID: 20491741
[TBL] [Abstract][Full Text] [Related]
14. Budesonide foam for mild to moderate distal ulcerative colitis: A systematic review and meta-analysis.
Zeng J; Lv L; Mei ZC
J Gastroenterol Hepatol; 2017 Mar; 32(3):558-566. PubMed ID: 27699863
[TBL] [Abstract][Full Text] [Related]
15. Budesonide for the treatment of ulcerative colitis.
Abdalla MI; Herfarth H
Expert Opin Pharmacother; 2016 Aug; 17(11):1549-59. PubMed ID: 27157244
[TBL] [Abstract][Full Text] [Related]
16. Budesonide foam vs. hydrocortisone acetate foam in the treatment of active ulcerative proctosigmoiditis.
Bar-Meir S; Fidder HH; Faszczyk M; Bianchi Porro G; Sturniolo GC; Mickisch O; Müller R; Greinwald R; Chowers Y; Grobeta V;
Dis Colon Rectum; 2003 Jul; 46(7):929-36. PubMed ID: 12847368
[TBL] [Abstract][Full Text] [Related]
17. A safety evaluation of budesonide MMX for the treatment of ulcerative colitis.
Bezzio C; Festa S; Zerboni G; Papi C; Manes G; Saibeni S
Expert Opin Drug Saf; 2018 Apr; 17(4):437-444. PubMed ID: 29473429
[TBL] [Abstract][Full Text] [Related]
18. Topical therapies in inflammatory bowel disease.
Frei P; Biedermann L; Manser CN; Wilk M; Manz M; Vavricka SR; Rogler G
Digestion; 2012; 86 Suppl 1():36-44. PubMed ID: 23051725
[TBL] [Abstract][Full Text] [Related]
19. Reviewing the therapeutic role of budesonide in Crohn's disease.
López-Sanromán A; Clofent J; Garcia-Planella E; Menchén L; Nos P; Rodríguez-Lago I; Domènech E
Gastroenterol Hepatol; 2018; 41(7):458-471. PubMed ID: 30007787
[TBL] [Abstract][Full Text] [Related]
20. Budesonide MMX in Paediatric Patients With Ulcerative Colitis.
Karolewska-Bochenek K; Dziekiewicz M; Banaszkiewicz A
J Crohns Colitis; 2017 Oct; 11(11):1402. PubMed ID: 28505293
[No Abstract] [Full Text] [Related]
[Next] [New Search]
